Testosterone Cypionate Auto-Injector (Azmiro)

Quick Reference Card

Overview / What Is Azmiro?

The Basics

Azmiro is a branded form of testosterone cypionate, the same medication that has been used for testosterone replacement therapy under the name Depo-Testosterone for decades. What sets Azmiro apart is its delivery format: it is the first and only FDA-approved prefilled syringe containing testosterone cypionate, designed to simplify the injection process for healthcare providers administering the medication.

If you have been diagnosed with hypogonadism (clinically low testosterone confirmed by blood tests and symptoms), Azmiro is one of several injectable testosterone options your provider might consider. It contains exactly the same active compound as Depo-Testosterone and generic testosterone cypionate. The difference lies in the packaging and presentation, not in the medication itself.

Azmiro was approved by the FDA in October 2024 and became commercially available in December 2024 through Azurity Pharmaceuticals. The prefilled syringe format eliminates the need for healthcare providers to draw up doses from a multi-dose vial, which reduces preparation steps and potential dosing errors in clinical settings. However, the prefilled syringe delivers a fixed 200 mg dose and is intended for administration by a healthcare professional, not for home self-injection.

For doses other than 200 mg, Azmiro is also available as a single-dose vial (200 mg/mL), which allows providers to measure and administer smaller doses as needed. This flexibility is important because most TRT protocols start at lower doses and titrate upward based on blood work and symptom response.

It is worth noting that testosterone cypionate, regardless of brand, is classified as a Schedule III controlled substance. It requires a valid prescription, and safety and efficacy for treating "age-related hypogonadism" (low testosterone due to aging rather than a diagnosed medical condition) have not been established by the FDA.

The Science

Azmiro (NDA216318) is a branded formulation of testosterone cypionate, the 17-beta-cyclopentylpropionate ester of the endogenous androgen testosterone. FDA approval was granted on October 4, 2024, to Slayback Pharma LLC (subsequently marketed by Azurity Pharmaceuticals, Inc.) based on the established safety and efficacy profile of testosterone cypionate, which has been available in the United States since 1953 [1].

The product is supplied as a sterile, clear colorless to pale yellow solution containing 200 mg/mL testosterone cypionate in cottonseed oil, with benzyl alcohol (20 mg/mL) as preservative and benzyl benzoate as solubilizer. It is available in two presentations: a single-dose vial and a single-dose prefilled syringe, both at the 200 mg/mL concentration [1][2].

The clinical significance of Azmiro lies not in a novel active pharmaceutical ingredient but in its delivery format innovation. The prefilled syringe reduces medication preparation steps in clinical settings and eliminates the need for dose measurement from multi-dose vials, potentially reducing dosing errors and contamination risk associated with repeated vial access. The prefilled syringe is restricted to healthcare professional administration and delivers a fixed 200 mg dose [2][3].

Azmiro's July 2025 label update incorporated revised warnings for venous thromboembolism (Section Section 4.2) and blood pressure increases (Section Section 4.4), aligning with broader FDA safety communications regarding testosterone products [1].

Medical / Chemical Identity

Generic Name: Testosterone Cypionate (Testosterone 17-beta-cyclopentylpropionate)

Brand Name:

• United States: Azmiro (Azurity Pharmaceuticals, Inc.)

Chemical Class: Androgen, Anabolic Steroid, Testosterone Ester (17-beta-ester derivative)

Ester Group: Cyclopentylpropionate (cyclopentyl-1-oxopropoxy at the 17-beta position)

• Carbon chain: 8-carbon ester side chain
• The ester group increases lipophilicity, slowing absorption from the intramuscular depot and extending duration of action

Chemical Name: Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17-beta)-

Molecular Formula: C27H40O3

Molecular Weight: 412.61 g/mol

CAS Number: 58-20-8

Physical Properties: White or creamy white crystalline powder, odorless or nearly so, stable in air. Insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils.

FDA Approval: NDA216318 (Azmiro, Azurity Pharmaceuticals). Original testosterone cypionate approval predates January 1, 1982.

DEA Classification: Schedule III Controlled Substance under the Anabolic Steroid Control Act

Formulations Available:

• 200 mg/mL single-dose vial in cottonseed oil with benzyl benzoate and benzyl alcohol (20 mg/mL)
• 200 mg/mL single-dose prefilled syringe in cottonseed oil with benzyl benzoate and benzyl alcohol (20 mg/mL)

NDC Numbers:

• 24338-055-01 (prefilled syringe, Azurity)
• 24338-056-01 (vial, Azurity)

Note on Interchangeability: The FDA label states that injectable testosterone products may have different doses, strengths, or administration instructions and they are not substitutable on a milligram-per-milligram basis. Azmiro should not be interchanged with other testosterone cypionate products without prescriber direction [1].

Mechanism of Action

The Basics

Testosterone is the primary male sex hormone, though calling it a "sex hormone" understates its role considerably. Testosterone influences nearly every system in the body: it maintains bone strength, builds and preserves muscle tissue, regulates mood and energy levels, supports cognitive function, stimulates red blood cell production, and plays a role in cardiovascular and metabolic health. When your body does not produce enough testosterone on its own, the effects can ripple across all of these areas.

Azmiro delivers testosterone cypionate, which is testosterone attached to a chemical "tail" called an ester. This ester acts as a time-release mechanism. Without it, injected testosterone would spike in your bloodstream and disappear within hours. The cypionate ester gives each injection a working life of roughly one to two weeks, which is why dosing schedules typically call for injections every two to four weeks (though many providers and patients prefer more frequent dosing for steadier levels).

Once injected into muscle tissue, your body's enzymes gradually detach the ester, releasing free testosterone into your bloodstream. From there, it works just like the testosterone your body makes naturally. Some of it gets converted to dihydrotestosterone (DHT), which is responsible for effects on hair, skin, and prostate tissue. Some gets converted to estradiol, a form of estrogen that men also need for bone health, brain function, and cardiovascular protection. Your provider monitors the balance between these hormones during treatment.

One important consequence of receiving testosterone from an outside source: your brain detects the higher testosterone levels and tells your body to reduce its own production. This is why natural testosterone production and sperm production decline while you are on TRT, and it is a key reason fertility should be discussed before starting treatment.

The Science

Testosterone cypionate functions as a prodrug of endogenous testosterone. Following deep intramuscular injection into the gluteal muscle in a cottonseed oil vehicle, the lipophilic ester is deposited in muscle tissue where it undergoes slow first-order absorption into systemic circulation. Non-specific esterases in plasma and tissues hydrolyze the ester bond at the C-17 position, liberating free testosterone [1][4].

Free testosterone exerts biological effects primarily through binding to the intracellular androgen receptor (AR), a member of the nuclear receptor superfamily. The classical genomic pathway involves ligand-AR binding, receptor dimerization, nuclear translocation, and interaction with androgen response elements (AREs) in target gene promoters, modulating transcription over hours to days. Non-genomic signaling through membrane-associated AR and SHBG receptor complexes activates rapid second messenger cascades (MAPK/ERK, PI3K/Akt, intracellular calcium) within seconds to minutes [4][5].

Testosterone undergoes two primary metabolic conversions:

1. 5-alpha reductase (types I and II) irreversibly converts testosterone to 5-alpha-dihydrotestosterone (DHT), which has approximately 2-3 times greater AR binding affinity and mediates androgenic effects in skin, hair follicles, and prostate tissue [5].
2. Aromatase (CYP19A1), expressed predominantly in adipose tissue, brain, and bone, converts testosterone to 17-beta-estradiol (E2). In men, estradiol is essential for bone mineral density maintenance (via ER-alpha-mediated osteoblast regulation), negative feedback on GnRH/LH secretion, and neuroprotective functions [4][5].

The HPG axis suppression by exogenous testosterone is mediated through both hypothalamic (reduced GnRH pulse frequency and amplitude) and pituitary (reduced LH and FSH synthesis and secretion) mechanisms. Intratesticular testosterone concentrations, normally maintained at 40-100 times serum levels by LH-stimulated Leydig cell production, decline to near-serum levels on exogenous TRT, resulting in impaired Sertoli cell function and spermatogenic arrest. The Azmiro prescribing information explicitly states that "the administration of exogenous testosterone suppresses spermatogenesis in the male" [1][5][6].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

Understanding how Azmiro moves through your body helps explain why injection timing and dose matter. Since Azmiro contains testosterone cypionate (the same compound as Depo-Testosterone and generic formulations), its behavior in the body is identical to all other testosterone cypionate products.

After injection into the gluteal muscle, the oil-based solution forms a small depot. Your body absorbs testosterone from this depot gradually over the following days and weeks. Testosterone levels typically peak within 24-48 hours after injection and then decline steadily. With a half-life of approximately 8 days, testosterone levels reach their lowest point (the "trough") around 7-10 days after injection.

This peak-trough pattern is why injection frequency matters. When injections are spaced far apart (every two weeks or longer), the swing between peak and trough can be significant. Some men notice they feel great for the first few days after injection but experience returning symptoms as levels drop before the next dose. More frequent injections at lower doses (weekly, twice weekly, or even more often) produce flatter, more stable testosterone levels, which some men and their providers prefer.

The prefilled syringe delivers a fixed 200 mg dose, which for many patients on a biweekly schedule would mean 200 mg every two weeks (equivalent to approximately 100 mg per week). For individualized dosing, the vial formulation allows providers to measure doses ranging from 50 to 400 mg.

About 44% of circulating testosterone is bound to sex hormone-binding globulin (SHBG), about 54% is bound to albumin, and roughly 2% circulates as free (unbound) testosterone. Free testosterone and albumin-bound testosterone are considered "bioavailable" because they can enter tissues and exert biological effects.

The Science

Testosterone cypionate (TC) administered intramuscularly as Azmiro follows the same pharmacokinetic profile as all other testosterone cypionate formulations at equivalent concentrations.

Absorption: Following deep gluteal IM injection in cottonseed oil, TC undergoes slow first-order absorption from the intramuscular depot. Peak serum testosterone concentrations (Cmax) of 800-1200 ng/dL are typically reached within 24-48 hours of a standard 100-200 mg IM injection [4][7].

Ester Hydrolysis: Non-specific tissue and plasma esterases cleave the cyclopentylpropionate ester at the C-17 position, releasing free testosterone. The rate of hydrolysis is the primary determinant of the apparent elimination half-life [4].

Distribution: Testosterone distributes extensively. Approximately 44% binds to SHBG with high affinity, 54% binds to albumin with lower affinity, and approximately 2% circulates as unbound free testosterone. Free and albumin-bound fractions constitute bioavailable testosterone [4][5].

Metabolism: Free testosterone undergoes hepatic and peripheral metabolism. The two clinically significant pathways are 5-alpha reduction to DHT (primarily in skin, prostate, and hair follicles) and aromatization to estradiol (primarily in adipose tissue, brain, and bone). Additional metabolic pathways involve glucuronidation and sulfation for renal excretion [4][5].

Elimination: The terminal elimination half-life of TC is approximately 8 days following IM injection. Trough levels at 7-10 days post-injection typically range from 300-600 ng/dL depending on dose and individual metabolism. Metabolites are excreted primarily via urine (approximately 90%) with a small fraction via feces [4][7].

Peak-Trough Dynamics: The peak-to-trough ratio with biweekly dosing is substantial and represents a key consideration in injection frequency selection. A population PK model of depot testosterone cypionate in healthy males estimated a clearance of 2.6 kL/day and volume of distribution of 14.4 kL [7]. More frequent lower-dose protocols (e.g., 50-100 mg weekly, 25-50 mg twice weekly) produce flatter concentration-time curves and may reduce side effects related to supraphysiological peaks [7][8].

Understanding how your testosterone ester is absorbed and metabolized is one thing. Tracking your actual injection protocol — doses, timing, and injection sites — gives you the data to have more productive conversations with your prescriber. Doserly lets you log every injection with ester-specific detail, building a clear record of your testosterone protocol over time.

Whether you're on cypionate twice weekly, enanthate every 3.5 days, or undecanoate every ten weeks, the app tracks your schedule and flags when your next dose is due. When your provider asks how your protocol has been going, you'll have a precise answer instead of a best guess.

Research & Clinical Evidence

The Basics

Azmiro contains the same medication (testosterone cypionate) that has been used in clinical practice since the 1950s. It does not introduce a new molecule or mechanism; it introduces a new delivery format (the prefilled syringe). Because of this, the clinical evidence for Azmiro's effectiveness comes from the broader testosterone cypionate and TRT literature rather than Azmiro-specific clinical trials.

The most important clinical study for understanding TRT safety is the TRAVERSE trial, published in 2023. This was the first large-scale randomized controlled trial specifically designed to evaluate whether TRT increases cardiovascular risk. The trial enrolled over 5,200 men aged 45-80 who had hypogonadism and either existing cardiovascular disease or significant risk factors. After an average follow-up of 33 months, the trial found that testosterone (administered as a gel, not injection) did not significantly increase the risk of major adverse cardiovascular events compared to placebo. This finding was reassuring but came with important caveats: the study used transdermal testosterone (not injectable like Azmiro), and it identified potential signals for increased atrial fibrillation, pulmonary embolism, and acute kidney injury that warrant continued monitoring.

Beyond cardiovascular safety, the TTrials (a coordinated set of seven clinical trials) demonstrated that testosterone therapy in older hypogonadal men improved sexual function, physical activity, mood, and bone density. These benefits were documented with transdermal testosterone but are expected to apply to injectable formulations like testosterone cypionate as well, since the active hormone reaching the bloodstream is identical regardless of delivery method.

The Science

Cardiovascular Safety (TRAVERSE Trial):
The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men; n=5,246) demonstrated non-inferiority of transdermal testosterone gel vs placebo for the primary composite endpoint of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) with a hazard ratio of 0.96 (95% CI: 0.78-1.17) over a mean follow-up of 33 months [9]. The upper bound of the 95% CI (1.17) was below the prespecified non-inferiority margin of 1.20, satisfying the primary safety endpoint.

Secondary cardiovascular findings included numerically higher rates of atrial fibrillation (HR 1.26, 95% CI: 0.93-1.69), pulmonary embolism (HR 1.92, 95% CI: 0.99-3.72), and acute kidney injury (HR 1.69, 95% CI: 1.05-2.73) in the testosterone group [9].

Hematologic Effects:
Testosterone stimulates erythropoiesis, with polycythemia (hematocrit >54%) being the most common dose-limiting adverse effect. Incidence is higher with injectable formulations (IM) than transdermal preparations, likely due to supraphysiological peaks following injection [8][10]. The Azmiro prescribing information mandates hematocrit monitoring prior to initiation and periodically thereafter [1].

Fertility Suppression:
A population PK/PD model of depot testosterone cypionate demonstrated dose-dependent suppression of LH and spermatogenesis, with estimated potency (IC50) of total testosterone for LH suppression at 9.33 ng/mL. Simulation indicated that 100 mg/week dosing would achieve near-complete suppression of endogenous testosterone secretion and significant spermatogenic impairment [7].

TTrials:
The Testosterone Trials (n=790, men >= 65 years with total testosterone <275 ng/dL) demonstrated significant improvements in sexual function (as measured by PDQ-Q4), physical activity, and depressive symptoms with 12 months of transdermal testosterone therapy. Bone mineral density improvements were documented in the Bone Trial sub-study [11].

Evidence & Effectiveness Matrix

The following matrix uses the 18 TRT symptom/outcome categories. Evidence Strength scores are derived from the broader testosterone cypionate and TRT clinical evidence base, which applies directly to Azmiro since it contains the same active compound. Reported Effectiveness scores are marked as not available because Azmiro-specific community data has not yet accumulated (the product became commercially available in December 2024).

Benefits & Therapeutic Effects

The Basics

The benefits of Azmiro are the benefits of testosterone cypionate, since the active medication is identical. When testosterone levels are restored to the normal physiological range in men with confirmed hypogonadism, several improvements are commonly observed.

Sexual function is often the first benefit men notice, typically within the first three to six weeks. This can include increased libido, improved erectile quality, and more frequent morning erections.

Energy and vitality tend to improve gradually, with many men reporting reduced fatigue and greater motivation within the first few months. The persistent exhaustion that often accompanies low testosterone can begin to lift, though the degree of improvement varies widely between individuals.

Body composition changes usually take longer to become apparent but are among the most consistent benefits. Men on TRT typically gain lean muscle mass and lose body fat over the first three to twelve months, assuming adequate nutrition and exercise.

Mood and emotional wellbeing often improve, with reductions in irritability, emotional flatness, and depressive symptoms. These changes can be subtle and gradual or, for some men, quite dramatic.

Bone density improvements develop over a longer timeframe (six to twelve months or more) and are particularly important for older hypogonadal men at risk for osteoporosis.

It is important to set realistic expectations. Not every symptom that prompted evaluation will resolve with TRT, and the degree of improvement varies based on individual factors including age, baseline testosterone levels, the underlying cause of hypogonadism, overall health, and lifestyle factors.

The Science

The therapeutic effects of Azmiro (testosterone cypionate) are mediated through androgen receptor activation across multiple target tissues and through conversion to DHT and estradiol.

Sexual Function: Testosterone therapy demonstrates the most consistent benefit in sexual desire/libido, with the TTrials reporting significant improvement in sexual activity, sexual desire, and erectile function scores (PDQ-Q4) compared to placebo over 12 months [11]. Erectile function improvement is more variable and depends on the etiology (hormonal vs vascular vs neurogenic).

Body Composition: Meta-analyses consistently demonstrate that TRT in hypogonadal men increases lean body mass by approximately 1.6-3.0 kg and decreases fat mass by approximately 1.5-2.5 kg over 6-12 months [8]. These effects are mediated through direct AR-mediated stimulation of myogenic stem cell differentiation and inhibition of adipocyte differentiation.

Bone Mineral Density: The TTrials Bone Trial demonstrated significant improvement in volumetric BMD of the spine (7.5% increase) and hip, mediated through both direct androgen receptor activation in osteoblasts and aromatization to estradiol for osteoclast inhibition [11].

Mood and Cognition: The TTrials demonstrated improvement in depressive symptoms (PHQ-9) but no significant improvement in objective cognitive function testing [11].

Erythropoiesis: Testosterone stimulates erythropoietin production and enhances erythroid progenitor cell differentiation, which is both a therapeutic effect (correction of anemia of hypogonadism) and a safety concern (polycythemia) [1][10].

Risks, Side Effects & Safety

The Basics

All testosterone products, including Azmiro, carry risks that require monitoring. Understanding these risks in context is important for making informed decisions with your healthcare provider.

Common side effects include injection site reactions (bruising, bleeding, redness, hardness at the injection site), acne or oily skin, fluid retention, and mood changes. These are usually mild and often improve as your body adjusts to treatment.

Polycythemia (elevated red blood cell count) is the most common laboratory abnormality requiring intervention. Testosterone stimulates red blood cell production, and hematocrit levels above 54% increase the risk of blood clots, stroke, and heart attack. Regular blood monitoring is mandatory. If hematocrit exceeds this threshold, your provider may reduce the dose, switch to a different route (transdermal products produce less hematocrit elevation than injections), or recommend therapeutic phlebotomy (blood donation). Injectable testosterone products like Azmiro tend to produce higher hematocrit elevations than gels or patches because of the supraphysiological peak levels following injection.

Cardiovascular risk has been extensively studied. The TRAVERSE trial (the largest randomized controlled trial designed to assess cardiovascular safety of TRT) enrolled over 5,200 men aged 45-80 with hypogonadism and cardiovascular risk factors. The primary finding was reassuring: testosterone therapy did not significantly increase the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared to placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months. However, the trial noted signals for increased risk of atrial fibrillation, pulmonary embolism, and acute kidney injury that warrant continued monitoring [9]. The Azmiro label includes a July 2025 update with revised warnings for venous thromboembolism and blood pressure increases [1].

Fertility suppression is a critical consideration discussed in detail in Section 14. Exogenous testosterone suppresses sperm production, and this effect is not always fully reversible.

Sleep apnea may worsen in some men, particularly those who are obese or have pre-existing breathing issues during sleep. Monitoring and screening are recommended before starting TRT [1].

Gynecomastia (breast tissue enlargement) can occur due to aromatization of testosterone to estradiol. This is listed as a specific warning in the Azmiro prescribing information [1].

Prostate effects require monitoring. While current evidence does not support a causal link between TRT at physiological levels and prostate cancer initiation, PSA should be monitored according to age-appropriate guidelines. TRT can exacerbate benign prostatic hyperplasia (BPH) symptoms [1].

The Science

Polycythemia:
Testosterone-induced erythrocytosis occurs through enhanced erythropoietin production and direct stimulation of erythroid progenitor cells. The hematocrit threshold for clinical intervention is >54%, at which point thrombotic risk increases significantly. Injectable formulations produce higher rates of polycythemia than transdermal preparations due to supraphysiological peak concentrations following injection. The Azmiro prescribing information mandates hematocrit monitoring prior to initiation and periodically thereafter, with dose reduction or discontinuation if levels become elevated [1][8][10].

Cardiovascular Events:
The TRAVERSE trial (n=5,246, men aged 45-80 with hypogonadism and cardiovascular risk factors or established CVD) demonstrated non-inferiority of testosterone gel vs placebo for the primary composite MACE endpoint with HR 0.96 (95% CI: 0.78-1.17) over 33 months [9]. Secondary cardiovascular outcomes included:

• Atrial fibrillation: HR 1.26 (95% CI: 0.93-1.69)
• Pulmonary embolism: HR 1.92 (95% CI: 0.99-3.72)
• Acute kidney injury: HR 1.69 (95% CI: 1.05-2.73)

The July 2025 Azmiro label update incorporated revised warnings for venous thromboembolism and blood pressure increases, consistent with the evolving post-TRAVERSE regulatory response [1].

Blood Pressure:
The Azmiro prescribing information warns of blood pressure increases, a concern supported by TRAVERSE trial findings showing a numerically small but clinically meaningful systolic BP increase associated with testosterone exposure. The SCTE-AI (subcutaneous testosterone enanthate auto-injector) Phase III trial similarly documented a 3-5 mmHg mean systolic BP increase, suggesting this is a class effect rather than route-specific [1][12].

Hepatotoxicity:
Hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis) are listed in the Azmiro warnings but are primarily associated with 17-alpha-alkylated oral androgens (e.g., methyltestosterone), not with injectable testosterone esters. The clinical relevance of these warnings for Azmiro is low [1].

Contraindications:
Absolute contraindications include breast cancer, known or suspected prostate cancer, and pregnancy or possibility of becoming pregnant. Testosterone is teratogenic and may cause virilization of the female fetus [1].

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're noticing acne, water retention, mood changes, or any other shift, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also tracks your hematocrit and PSA values over time, alerting you when levels approach thresholds that need attention.

Dosing & Treatment Protocols

The Basics

Azmiro is available in two forms, each serving different dosing needs. The prefilled syringe delivers a fixed 200 mg dose and is designed for healthcare professional administration. The single-dose vial (200 mg/mL) allows your provider to measure and inject any dose between 50 and 400 mg.

The FDA-approved dosing range for Azmiro is 50 mg to 400 mg administered every two to four weeks as a deep intramuscular injection in the gluteal muscle. Your provider will individualize your dose and schedule based on your age, diagnosis, response to treatment, and whether side effects develop.

In practice, most TRT protocols start at the lower end of the dosing range and titrate upward based on trough testosterone levels and symptom response, typically reassessing at 4-6 weeks. The goal is to achieve trough testosterone levels within the normal physiological range (generally 300-1000 ng/dL, with many guidelines targeting 450-600 ng/dL at trough).

Important: The prefilled syringe should be administered by a healthcare professional only and delivers only the 200 mg dose. It is not designed for patient self-injection or for dose splitting.

The Science

FDA-Approved Dosing:
Azmiro's approved dosing range is 50-400 mg IM every 2-4 weeks. The prescribing information requires confirmation of hypogonadism with subnormal serum testosterone concentrations prior to initiation [1].

Commonly Prescribed Protocols:

• Standard protocol: 100-200 mg IM every 1-2 weeks
• Split-dose protocol: 50-100 mg IM or subcutaneous twice weekly (off-label for Azmiro)
• The Endocrine Society Clinical Practice Guideline (2018) recommends testosterone cypionate 75-100 mg IM weekly or 150-200 mg IM every 2 weeks as starting regimens, titrating to achieve midnormal testosterone levels [8]

Monitoring and Titration:

• Check trough testosterone levels 4-6 weeks after initiation or dose adjustment
• Trough levels should be drawn just before the next scheduled injection
• Target: Trough testosterone in the normal range (varies by lab; commonly 300-1000 ng/dL)
• Hematocrit monitoring at baseline, 3-6 months, then annually
• PSA monitoring per age-appropriate guidelines
• Adjust dose based on symptoms, trough levels, and adverse effects [1][8]

Dosing protocols often change over the course of treatment. Starting doses get adjusted, injection frequencies get split, esters get switched. Doserly maintains a complete history of every protocol change, giving you and your provider a clear picture of what's been tried and how each adjustment affected your symptoms and lab values.

The app's adherence analytics show your consistency patterns and can highlight whether missed doses or timing variations correlate with symptom changes. When your provider is considering a dose adjustment based on your trough levels, having this data available makes the conversation more productive and the decision more informed.

What to Expect (Timeline)

The following timeline represents typical responses to testosterone cypionate therapy. Individual responses vary significantly. Azmiro contains the same medication as generic testosterone cypionate, so the expected timeline is identical.

Days 1-7: Possible injection site soreness (bruising, redness, hardness). Some men report a subtle mood or energy shift, though this early it is often partly placebo effect. Testosterone levels peak within 24-48 hours post-injection then begin declining.

Weeks 2-4: Libido changes are often the first noticeable effect. Some men notice improved energy and a subtle lift in mood. Sleep quality may begin changing (positively or negatively). Blood levels are still stabilizing.

Months 1-3: Sexual function improvements become more consistent. Energy and motivation may improve noticeably. Initial body composition changes begin (increased muscle fullness, early fat redistribution). Hematocrit may begin rising. This is when the first follow-up blood work typically occurs (4-12 weeks). Dose adjustment may be considered based on trough levels and symptom response.

Months 3-6: Body composition changes become more visible (fat loss, lean mass increase). Strength improvements noticeable if exercising regularly. Mood stabilization. Hematocrit should be rechecked. PSA should be monitored per age-appropriate guidelines. If prescribed at biweekly intervals, some men may notice symptom cyclicity (feeling good after injection, declining before next dose).

Months 6-12: Full sexual function benefits typically realized. Significant body composition changes. Bone density improvements begin (measurable by DEXA). Ongoing monitoring: hematocrit, testosterone levels, PSA, lipid panel.

Ongoing Maintenance: Annual comprehensive review with provider. Continued monitoring of hematocrit (>54% threshold), PSA, lipid panel. Dose reassessment as needed. Discussion of continued appropriateness of therapy.

Realistic Expectations: Not every symptom resolves with TRT. The degree of improvement varies based on age, baseline testosterone levels, the underlying cause of hypogonadism, overall health, genetics, and lifestyle factors (diet, exercise, sleep, stress management). Some benefits take months to fully manifest. Dose adjustment during the first several months is common and expected.

Fertility Preservation & HPG Axis

This section is mandatory for all testosterone compound guides.

Exogenous testosterone, including Azmiro, suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This means that when your body receives testosterone from an outside source, your brain signals your testes to stop producing testosterone on their own. As a consequence, sperm production declines significantly.

How suppression works: Exogenous testosterone provides negative feedback to the hypothalamus and pituitary gland, suppressing gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Without adequate LH and FSH stimulation, the testes reduce both testosterone and sperm production. Intratesticular testosterone concentrations (normally 40-100 times higher than blood levels) decline dramatically, leading to Sertoli cell dysfunction and spermatogenic arrest. The Azmiro prescribing information explicitly states that "the administration of exogenous testosterone suppresses spermatogenesis in the male" [1].

Timeline of suppression: Sperm counts typically decline within 2-3 months of starting TRT. Approximately 40-60% of men on testosterone therapy develop azoospermia (zero sperm count) by 6 months, with the remainder usually showing severe oligospermia (very low sperm counts) [7].

Fertility preservation strategies:

• Sperm banking: Consider banking sperm before starting TRT if you may want biological children in the future. This is the most reliable preservation strategy.
• HCG co-administration: Human chorionic gonadotropin (250-500 IU, 2-3 times weekly) can maintain intratesticular testosterone and partial spermatogenesis during TRT. Evidence is supportive but not from large RCTs, and effectiveness varies.
• Clomiphene/enclomiphene alternatives: For men prioritizing fertility, selective estrogen receptor modulators (SERMs) can stimulate endogenous testosterone production via LH/FSH increase without suppressing spermatogenesis. These are used as alternatives to exogenous testosterone, not alongside it in most protocols.

Recovery after discontinuation: If TRT is discontinued, HPG axis recovery and spermatogenesis resumption are possible but variable. Recovery timelines range from 6-24 months or longer, and full recovery to pre-TRT sperm counts is not guaranteed. Factors affecting recovery include duration of TRT use, age, pre-TRT hormonal status, and whether HCG was used during treatment.

Primary vs secondary hypogonadism: Men with primary hypogonadism (testicular failure) may have limited recovery potential regardless, since the underlying testicular pathology persists. Men with secondary hypogonadism (hypothalamic/pituitary dysfunction) generally have a better prognosis for HPG axis recovery.

Clinical importance: Fertility counseling should be part of every TRT initiation conversation for men of reproductive age. This is not a minor side effect. The decision to start TRT should include clear discussion of fertility implications with your healthcare provider.

Interactions & Compatibility

Drug-Drug Interactions:

• Anticoagulants (warfarin, phenprocoumon, dicumarol, anisindione): Testosterone may enhance anticoagulant effect, requiring INR monitoring and dose adjustment [1]
• Insulin and diabetes medications: Testosterone may improve insulin sensitivity, potentially requiring diabetes medication dose adjustment [1]
• Corticosteroids: Additive fluid retention effect [1]
• Bupropion: Listed interaction; clinical significance varies [1]
• Paclitaxel: Listed interaction; monitor if co-administered [1]

Supplement Interactions:

• DHEA: Additive androgenic effects; may increase estrogen conversion. See DHEA guide
• Boron: May increase free testosterone by reducing SHBG. See Boron guide
• Zinc: Supports testosterone production; co-supplementation generally safe. See Zinc guide
• Saw Palmetto: 5-alpha reductase inhibition may affect DHT conversion. See Saw Palmetto guide

Lifestyle Factors:

• Alcohol: Suppresses testosterone production and increases aromatization; limit consumption during TRT
• Sleep: Critical for hormonal health; TRT may worsen sleep apnea in susceptible individuals
• Exercise: Resistance training is synergistic with TRT for body composition and strength outcomes
• Body composition: Weight loss alone may normalize testosterone in obese men, potentially reducing the need for TRT

Related Guides:

• Testosterone Cypionate (Depo-Testosterone) — same active compound, conventional vial formulation
• Testosterone Enanthate (Delatestryl) — alternative injectable ester
• Testosterone Enanthate Auto-Injector (Xyosted) — subcutaneous auto-injector (different compound, different route, patient self-administered)
• Anastrozole — aromatase inhibitor sometimes co-prescribed
• HCG — co-administered for fertility preservation

Decision-Making Framework

Is Azmiro the right testosterone formulation for you?

The decision to use Azmiro specifically (rather than another testosterone formulation) depends on several factors that you should discuss with your provider:

When Azmiro may be appropriate:

• You prefer to receive injections at your provider's office rather than self-injecting at home
• Your provider prefers the convenience and reduced preparation time of a prefilled syringe
• You have been prescribed a 200 mg dose that aligns with the prefilled syringe format
• You have allergies or sensitivities to ingredients in other testosterone cypionate formulations (check inactive ingredients)

When another formulation may be more suitable:

• You prefer to self-inject at home (the Azmiro prefilled syringe is for healthcare professional administration only)
• You need dose flexibility (doses other than 200 mg from the prefilled syringe require using the vial formulation)
• Cost is a significant factor (generic testosterone cypionate from multi-dose vials is substantially less expensive)
• You prefer more frequent injection schedules (weekly, twice weekly, or more) that may not align with the prefilled syringe presentation

Diagnostic criteria for TRT (regardless of formulation):

• The Endocrine Society requires two morning total testosterone measurements below the lower limit of normal (typically <264-300 ng/dL, varies by lab) plus symptoms
• The AUA uses a 300 ng/dL threshold
• The EAU uses 12.1 nmol/L (~350 ng/dL)
• Reversible causes should be investigated first: obesity, sleep apnea, opioid use, pituitary pathology, thyroid dysfunction

Questions to ask your provider:

• Why is Azmiro being recommended rather than generic testosterone cypionate?
• Will I be able to adjust my dose and injection frequency over time?
• What monitoring schedule will we follow?
• What are the fertility implications, and should I consider sperm banking?
• What is the out-of-pocket cost compared to alternatives?

Administration & Practical Guide

Azmiro Administration:

Azmiro is administered by deep intramuscular injection into the gluteal muscle (buttock). The injection should be given by a healthcare professional.

Prefilled Syringe:

• Contains a single fixed dose of 200 mg testosterone cypionate (200 mg/mL, 1 mL)
• Designed for healthcare professional administration only
• Should only be used for the 200 mg dose; cannot be used for partial doses
• Disposed of after single use

Vial:

• Contains 200 mg/mL testosterone cypionate in a single-dose vial
• Allows flexible dosing (50-400 mg range as prescribed)
• Healthcare professional draws up the prescribed amount using appropriate syringe and needle
• The vial is single-dose and should not be reused

Injection Technique (administered by healthcare provider):

• Site: Deep gluteal intramuscular injection (ventrogluteal or dorsogluteal muscle)
• Needle: Typically 21-23 gauge, 1-1.5 inch length
• The injection should be administered slowly to reduce injection site discomfort
• Aspiration before injection is debated; follow your facility's protocol

Important Distinction: Unlike Xyosted (testosterone enanthate subcutaneous auto-injector), which is designed for patient self-administration at home, Azmiro's prefilled syringe is intended for use by healthcare professionals. If you wish to self-inject testosterone at home, discuss alternative formulations with your provider, such as generic testosterone cypionate from a multi-dose vial, which your provider can teach you to administer.

Post-Injection:

• Mild soreness, bruising, or redness at the injection site is common
• Report significant pain, swelling, or signs of infection to your provider
• The injection site should be rotated between buttocks to minimize tissue irritation

Monitoring & Lab Work

Pre-TRT Baseline Labs:

• Total testosterone (two morning draws, before 10 AM)
• Free testosterone (calculated or equilibrium dialysis)
• LH, FSH (to distinguish primary vs secondary hypogonadism)
• Estradiol
• SHBG
• Prolactin (if secondary hypogonadism suspected)
• CBC with hematocrit
• PSA (age-appropriate)
• Lipid panel
• Comprehensive metabolic panel
• DEXA if osteoporosis risk

Initial Follow-Up (4-12 weeks):

• Trough testosterone level (drawn just before next scheduled injection)
• Hematocrit
• Symptom assessment
• Side effect evaluation
• Dose adjustment consideration

Ongoing Monitoring Schedule:

• Hematocrit: Every 6-12 months; threshold >54% for intervention (dose reduction, phlebotomy, route change)
• PSA: Per age-appropriate screening guidelines; annually for men >40
• Testosterone levels: Trough levels for injectables
• Estradiol: Only if symptomatic (gynecomastia, fluid retention, mood), not routine per guidelines
• Lipid panel: Annually
• Bone density (DEXA): If osteoporosis was an indication, repeat per clinical protocol
• Semen analysis: If fertility is a concern

Annual Review Checklist:

• Symptom reassessment
• Review of continued indication for TRT
• Risk-benefit discussion
• Dose optimization
• Screening for sleep apnea symptoms
• Blood pressure monitoring

Estrogen Management on TRT

Testosterone is converted to estradiol by the aromatase enzyme (CYP19A1), primarily in adipose tissue. This conversion is a normal physiological process, and men need estradiol for bone health, cardiovascular protection, brain function, and libido.

When estrogen management matters: Only when clinical symptoms of elevated estrogen are present (gynecomastia, significant fluid retention, emotional lability, nipple sensitivity) or when estradiol levels are clearly elevated on lab work. The Azmiro prescribing information lists gynecomastia as a specific warning [1].

Aromatase inhibitors: Anastrozole (0.25-0.5 mg, 2-3 times weekly) is the most commonly used AI in TRT contexts. However, the Endocrine Society and AUA guidelines do not recommend routine AI use during TRT. Suppressing estradiol too aggressively causes joint pain, mood disturbance, decreased libido, and bone density loss.

High E2 symptoms: Breast tissue growth (gynecomastia), excessive fluid retention, emotional lability, nipple sensitivity.

Low E2 symptoms: Joint pain/stiffness, low libido (paradoxically), dry skin, fatigue, depression, bone density loss.

Clinical guidelines vs community practice: Clinical guidelines recommend symptom-based estrogen management, not routine number-chasing. Many online TRT communities emphasize maintaining estradiol within a specific target range (often 20-35 pg/mL), but this approach is not evidence-based and carries risks of over-suppression.

Stopping TRT / Post-Cycle Considerations

Is TRT with Azmiro lifelong?

For many men with classical hypogonadism (particularly primary hypogonadism from testicular failure), testosterone therapy is typically a lifelong treatment because the underlying condition does not resolve. For men with secondary hypogonadism, addressing underlying causes (weight loss, sleep apnea treatment, opioid cessation) may restore endogenous production, potentially allowing discontinuation.

What happens when TRT is stopped:
When exogenous testosterone is discontinued, LH and FSH remain suppressed for weeks to months. Endogenous testosterone production may take 6-24+ months to recover, and recovery to pre-TRT levels is not guaranteed. During this period, symptoms of low testosterone typically return (fatigue, low libido, mood changes, loss of muscle mass).

Recovery support (PCT protocols):
These are community-derived protocols adapted from anabolic steroid use and are not standardized in clinical guidelines for TRT discontinuation:

• HCG taper: 1000-2000 IU every other day for 2-4 weeks, then taper
• Clomiphene citrate: 25-50 mg daily for 4-8 weeks to stimulate LH/FSH recovery
• Enclomiphene: Newer SERM with potentially fewer side effects
• Tamoxifen: 10-20 mg daily for 4-6 weeks (less commonly used)

Factors affecting recovery: Duration of TRT use (longer = slower recovery), age, pre-TRT hormonal status, concurrent HCG use during TRT, individual genetic factors.

Realistic expectations: Not everyone recovers fully. Some men return to pre-TRT levels, some recover partially, and some do not recover meaningfully. This should be discussed before starting TRT.

Special Populations & Situations

Obese Men

Weight loss alone may normalize testosterone levels in obese men. The Endocrine Society recommends addressing obesity through lifestyle intervention before initiating TRT. If TRT is started, higher aromatization may occur due to increased adipose tissue, potentially requiring closer estradiol monitoring.

Men with Sleep Apnea

TRT may exacerbate obstructive sleep apnea. CPAP optimization before and during TRT is recommended. The Azmiro prescribing information warns of potential sleep apnea worsening [1].

Men with Prostate Cancer History

Historically an absolute contraindication. The saturation model suggests that at physiological testosterone levels, further androgen receptor stimulation does not meaningfully increase prostate tissue growth. However, this remains an evolving area requiring specialized urological consultation.

Cardiovascular Disease History

TRAVERSE provides reassurance of non-inferiority for MACE. Hematocrit monitoring is critical given the higher polycythemia risk with injectable formulations. Blood pressure monitoring is especially important given the July 2025 Azmiro label update [1][9].

Type 2 Diabetes

TRT may improve insulin sensitivity and metabolic parameters in hypogonadal diabetic men. Diabetes medication adjustment may be needed [1].

Adolescents and Young Men

Safety and efficacy of Azmiro in children younger than 12 years have not been established. Androgens may accelerate bone maturation without compensatory gain in linear growth, potentially leading to shortened adult height. Fertility implications are especially critical in this population [1].

Transgender Men (FTM)

Different dosing goals (masculinizing doses). Voice changes are permanent. Fertility counseling (oocyte preservation) is essential before initiating treatment. Azmiro could be used but is not specifically labeled for this indication.

Older Men (>65)

The distinction between age-related testosterone decline and true hypogonadism is critical. TRAVERSE and TTrials data are primarily from this population. Lower starting doses are often appropriate. Increased polycythemia risk. Prostate monitoring heightened. The Azmiro label notes that safety and efficacy for age-related hypogonadism have not been established [1].

Regulatory, Insurance & International

United States:

• Azmiro is FDA-approved (NDA216318, October 2024) for TRT in males with primary or hypogonadotropic hypogonadism
• Classified as Schedule III controlled substance (DEA)
• Safety and efficacy for age-related hypogonadism not established
• Available as 200 mg/mL single-dose vial and 200 mg/mL prefilled syringe
• Manufactured by Azurity Pharmaceuticals, Inc. (Woburn, MA)
• July 2025 label update added VTE and blood pressure warnings

Insurance and Cost:

• Azmiro is a branded product and may not be covered by all insurance plans
• Prior authorization may be required
• Cost without insurance: approximately $110/month (based on community reports for two prefilled syringes)
• Generic testosterone cypionate (multi-dose vials) is substantially less expensive (approximately $30-50 for a 10 mL multi-dose vial lasting 2-3 months)
• Patients should discuss cost comparison with their provider and pharmacist

International Availability:

• Azmiro is currently a US-only product
• Testosterone cypionate (the same active compound) is predominantly used in North America
• Most other regions (UK, Europe, Australia) use testosterone enanthate or undecanoate as primary injectable formulations
• International travelers on Azmiro should carry prescription documentation for Schedule III controlled substance transport

Frequently Asked Questions

What is the difference between Azmiro and Depo-Testosterone?
Both contain testosterone cypionate and work identically. The difference is packaging: Azmiro is available as both a vial and a prefilled syringe, while Depo-Testosterone comes only in vials. Azmiro is manufactured by Azurity Pharmaceuticals; Depo-Testosterone by Pfizer. The active medication, mechanism of action, and clinical effects are the same.

Is Azmiro an auto-injector?
No. Despite the guide title using "auto-injector" colloquially, Azmiro is a prefilled syringe, not an auto-injector in the traditional sense. Unlike Xyosted (testosterone enanthate subcutaneous auto-injector), which uses a spring-loaded mechanism for patient self-administration, Azmiro's prefilled syringe is a conventional syringe that must be administered by a healthcare professional via deep intramuscular injection.

Can I self-inject Azmiro at home?
The Azmiro prefilled syringe is labeled for administration by a healthcare professional only. If you prefer home self-injection, discuss alternative formulations with your provider, such as generic testosterone cypionate from multi-dose vials.

Is Azmiro more effective than generic testosterone cypionate?
No. Azmiro contains the same active medication (testosterone cypionate 200 mg/mL) as generic formulations. The therapeutic effects are identical. The difference is the convenience of the prefilled syringe format for clinical settings.

Why is Azmiro more expensive than generic testosterone cypionate?
Azmiro is a branded product with the additional cost of the prefilled syringe device and new NDA development. Generic testosterone cypionate from multi-dose vials is significantly less expensive.

How often do I need injections with Azmiro?
The FDA-approved dosing interval is every 2-4 weeks. Many providers adjust injection frequency based on individual response, with weekly injections being common in current practice. Discuss the optimal schedule with your provider.

Will Azmiro affect my fertility?
Yes. All exogenous testosterone, including Azmiro, suppresses sperm production. This effect may not be fully reversible. If you plan to have biological children, discuss fertility preservation options (sperm banking, HCG co-administration) with your provider before starting treatment.

Does Azmiro cause hair loss?
Testosterone is converted to DHT, which can accelerate male pattern baldness in genetically predisposed individuals. This is a class effect of all testosterone products, not specific to Azmiro.

Can Azmiro raise my blood pressure?
Yes. The Azmiro prescribing information includes warnings about blood pressure increases. Regular blood pressure monitoring is recommended, especially for those with pre-existing hypertension.

Is Azmiro safe for long-term use?
Long-term safety data specific to Azmiro is limited (product available since December 2024). However, testosterone cypionate as a compound has been used for over 70 years. The TRAVERSE trial provides the most robust long-term cardiovascular safety data for TRT. Ongoing monitoring (hematocrit, PSA, blood pressure, lipids) is essential throughout treatment.

Do I need to see my doctor every two weeks for an Azmiro injection?
If using the prefilled syringe, yes, you would need healthcare professional administration. Alternatively, your provider may prescribe the Azmiro vial and teach you to self-inject, or switch to a generic testosterone cypionate formulation for home administration.

Is Azmiro the same as Xyosted?
No. Azmiro contains testosterone cypionate for intramuscular injection by a healthcare professional. Xyosted contains testosterone enanthate for subcutaneous self-injection via an auto-injector device. They are different compounds, different routes, and different delivery devices.

Myth vs. Fact

Myth: Azmiro is a new, different type of testosterone.
Fact: Azmiro contains testosterone cypionate, the same compound that has been used for TRT since the 1950s. What is new is the delivery format (prefilled syringe). The medication, its effects, and its risks are identical to Depo-Testosterone and generic testosterone cypionate.

Myth: TRT causes heart attacks.
Fact: The TRAVERSE trial (n=5,246, the largest cardiovascular safety trial of TRT) found no significant increase in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) with testosterone vs placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months in men with cardiovascular risk factors. However, secondary signals for atrial fibrillation and pulmonary embolism warrant monitoring [9].

Myth: TRT causes prostate cancer.
Fact: Current evidence does not support a causal link between physiological TRT and prostate cancer initiation. The androgen receptor saturation model suggests that prostate tissue is maximally stimulated at relatively low testosterone levels, and further increases do not proportionally increase risk. However, TRT is contraindicated in men with known or suspected prostate cancer, and PSA monitoring during treatment is standard practice [1].

Myth: A prefilled syringe means I can inject myself at home.
Fact: The Azmiro prefilled syringe is specifically labeled for administration by a healthcare professional. It is not an auto-injector or home self-injection device. For self-injection, discuss generic testosterone cypionate from vials with your provider.

Myth: Once you start TRT you can never stop.
Fact: Discontinuation is possible, but the body's natural testosterone production may take 6-24+ months to recover, and full recovery is not guaranteed. The decision depends on the underlying cause of hypogonadism and individual factors. This should be discussed before starting treatment.

Myth: TRT will make you permanently infertile.
Fact: TRT suppresses sperm production, sometimes to zero (azoospermia). In most men, spermatogenesis recovers after TRT is discontinued, but the timeline is variable (6-24+ months), and recovery is not guaranteed in all cases. Sperm banking before TRT is recommended for men who may want biological children [7].

Myth: Higher testosterone doses always produce better results.
Fact: Benefits of TRT follow a dose-response curve with diminishing returns above the normal physiological range. Higher doses increase the risk of polycythemia, elevated blood pressure, worsened lipid profiles, and other side effects. The goal of TRT is restoration to the normal range, not supraphysiological levels [1][8].

Myth: All testosterone products are the same.
Fact: While different testosterone products all deliver the same hormone, they differ in ester type (affecting half-life and injection frequency), route of administration (IM, SubQ, transdermal, oral, nasal, pellet), delivery format (vial, prefilled syringe, auto-injector, gel, patch), and cost. These differences affect dosing convenience, side effect profiles (particularly polycythemia risk), and patient experience.

Myth: TRT clinics are all the same quality.
Fact: There is significant quality variance among TRT providers. Red flags include providers who prescribe without adequate baseline testing, who use cookie-cutter protocols without individualization, who routinely co-prescribe AI from the start, or who promise results beyond what evidence supports. Seek providers who follow evidence-based guidelines (Endocrine Society, AUA) and perform comprehensive monitoring.

Sources & References

Clinical Guidelines

[1] AZMIRO (testosterone cypionate) injection prescribing information. Azurity Pharmaceuticals, Inc. Revised July 2025. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235b5625-570d-3fba-e063-6394a90aa2d1

[2] Azurity Pharmaceuticals, Inc. "Announces Availability of AZMIRO (testosterone cypionate) injection for intramuscular use, CIII." Press Release. December 11, 2024.

[3] Endocrinology Advisor. "Azmiro Prefilled Syringe Now Available for Testosterone Replacement." December 2024.

Clinical Practice Guidelines

[4] Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

[5] Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.

Landmark Trials

[6] Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons From the Testosterone Trials. Endocr Rev. 2018;39(3):369-386.

Pharmacokinetic Studies

[7] Surampudi P, Kocur J, Engmann NJ, et al. Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects. J Clin Pharmacol. 2018;58(6):770-782.

Endocrine Society / Clinical Guidelines

[8] Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.

Cardiovascular Safety

[9] Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. (TRAVERSE Trial)

Polycythemia and Safety

[10] Jones SD Jr, Dukovac T, Engermann N, et al. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sex Med Rev. 2015;3(2):101-112.

TTrials

[11] Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624.

Auto-Injector Safety Data

[12] Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. J Sex Med. 2019;16:1741-1748.

Related Guides & Cross-Links

Same Category (Injectable Testosterone)

• Testosterone Cypionate (Depo-Testosterone) — same active compound, conventional vial formulation
• Testosterone Enanthate (Delatestryl) — alternative injectable ester with similar PK profile
• Testosterone Undecanoate Injectable (Aveed/Nebido) — long-acting injectable (every 10-14 weeks)
• Testosterone Enanthate Auto-Injector (Xyosted) — subcutaneous auto-injector for patient self-administration
• Sustanon 250 — multi-ester blend, primarily available outside the US

Related Treatment Options

• Testosterone Gel (AndroGel) — transdermal alternative
• Testosterone Patch (Androderm) — transdermal patch alternative
• Testosterone Injections Guide — comprehensive overview of all injectable TRT options

Ancillary Medications

• HCG — fertility preservation during TRT
• Anastrozole — aromatase inhibitor for estrogen management
• Clomiphene — SERM alternative to exogenous testosterone
• Enclomiphene — newer SERM with potentially fewer side effects

Conditions

• Primary Hypogonadism
• Secondary Hypogonadism
• Late-Onset Hypogonadism

Educational

• TRT for Beginners — starting guide for new TRT patients
• TRT Blood Work Guide — understanding your lab results
• Fertility Preservation on TRT
• Estrogen Management on TRT